A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

Ashique, Sumel; Sandhu, Navjot Kaur; Haque, Sk. Niyamul; Koley, Kartick

doi:10.2174/2666796701999201204123259

COVID

2021

DOI: 10.2174/2666796701999201204123259

|View full text |Cite

A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

Sumel Ashique

Navjot Kaur Sandhu

Sk. Niyamul Haque³

et al.

Abstract: : A coronavirus is a group of nonsegmented, single-stranded, enveloped viruses having positive RNA genomes. This virus was first described in 1931 and the first coronavirus was isolated (HCoV-229E) from humans in 1965. People become infected with four human coronavirus strains: 229E, NL63, OC43, and HKU1 which cause respiratory associated problems such as SARS and MERS. Lately, a new version of a strain called SARD-CoV-2 has been found. WHO called it novel coronavirus–infected pneumonia (NCIP) and later offici… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review

Ashique¹,

Khatun²,

Sahu³

et al. 2022

IDDT

View full text Add to dashboard Cite

To date, no accepted therapy exists for treating the emerging infectious disease nCOVID-19 in a safe and effective way. Although various types of treatment options are under the developing phase around the world, among those, several studies concerning convalescent plasma (CP) from recovered patients reported promising effects against nCOVID-19 infected critically ill patients nowadays. The therapy showed very few adverse effects, and it helps to diminish the viral load when administered at an early stage of infection. Convalescent plasma appears to be safe for critically ill nCOVID-19 patients by decreasing serum viral loads, and most cases are virus negative after CP transfusion. The convalescent plasma can be good as it has already been utilized to treat previous pandemics like Ebola, influenza, and SARS-CoV infection. In this review article, we pointed out the background, rationality, mechanisms, and safety outcomes of CP to treat nCOVID-19 infected patients.

show abstract

‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review

Ashique¹,

Khatun²,

Sahu³

et al. 2022

IDDT

View full text Add to dashboard Cite

show abstract

Advancement of Computational Design Drug Delivery System in COVID- 19: Current Updates and Future Crosstalk- A Critical Update

Mohiuddin

Mondal

2023

IDDT

View full text Add to dashboard Cite

Positive strides have been achieved in developing vaccines to combat the coronavirus-2019 infection (COVID-19) pandemic. Still, the outline of variations, particularly the most current delta divergent, has posed significant health encounters for people. Therefore, developing strong treatment strategies, such as an anti-COVID-19 medicine plan, may help deal with the pandemic more effectively. During the COVID-19 pandemic, some drug design techniques were effectively used to develop and substantiate relevant critical medications. Extensive research, both experimental and computational, has been dedicated to comprehending and characterizing the devastating COVID-19 disease. The urgency of the situation has led to the publication of over 130,000 COVID-19-related research papers in peer-reviewed journals and preprint servers. A significant focus of these efforts has been the identification of novel drug candidates and the repurposing of existing drugs to combat the virus. Many projects have utilized computational or computer-aided approaches to facilitate their studies. In this overview, we will explore the key computational methods and their applications in the discovery of small-molecule therapeutics for COVID-19, as reported in the research literature. We believe that the true effectiveness of computational tools lies in their ability to provide actionable and experimentally testable hypotheses, which in turn facilitate the discovery of new drugs and combinations thereof. Additionally, we recognize that open science and the rapid sharing of research findings are vital in expediting the development of much-needed therapeutics for COVID-19.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Recent Update on Therapeutics to Treat Emerging n-COVID 19: A Review

Cited by 2 publications

References 89 publications

‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review

‘Convalescent Plasma’- An Effective Treatment Option to Prevent Emerging nCOVID-19- A Review

Advancement of Computational Design Drug Delivery System in COVID- 19: Current Updates and Future Crosstalk- A Critical Update

Contact Info

Product

Resources

About